Open an account

IGM Biosciences LLC

IGMS · NASDAQ

Price unavailable right now.

No price history for this range.

About IGMS

IGM Biosciences, Inc. operates as a biotechnology company, which develops antibodies for the treatment of cancer. The company is headquartered in Mountain View, California and currently employs 16 full-time employees. The firm is engaged in developing and delivering a new class of medicines to treat patients with cancer and autoimmune and inflammatory diseases. The Company’s pipeline of clinical and preclinical assets is based on the IgM antibody, which has 10 binding sites compared to conventional IgG antibodies with only two binding sites. The company is also focused on creating, developing, manufacturing, and commercializing IgM antibody agonists against oncology and immunology and inflammation targets. The Company’s development programs include Aplitabart, Imvotamab, and IGM-2644. Aplitabart is an IgM antibody targeting Death Receptor 5 (DR5) proteins, being evaluated in multiple phase I combination trials for the treatment of colorectal cancer. Imvotamab is a bispecific T cell engaging IgM antibody targeting CD20 and CD3 proteins.

Employees
16
Headquarters
Mountain View, California
Listed
Sep 18, 2019
Sector
Health Care
Industry
Biotechnology
Website
igmbio.com

IGMS key statistics

This section is temporarily unavailable. Refresh to try again.

IGMS earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 131.5% on average.

  1. Q3 FY23: reported -$1.04 per share against an estimate of -$1.24
  2. Q4 FY23: reported -$1.01 per share against an estimate of -$1.05
  3. Q1 FY24: reported -$0.83 per share against an estimate of -$0.848
  4. Q2 FY24: reported -$0.79 per share against an estimate of -$0.0385
  5. Q3 FY24: reported -$1.01 per share against an estimate of -$0.816
  6. Q4 FY24: reported -$0.61 per share against an estimate of -$0.7528
  7. Q1 FY25: reported -$0.51 per share against an estimate of -$0.4182
  8. Q2 FY25: reported $1.58 per share against an estimate of -$0.306

IGMS news

  • Press releasePRNewswire

    $HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger: GMS, IGMS, MRC, and GRYP

  • Press releasePRNewswire

    SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GNTY, IGMS, SPTN, DNOW on Behalf of Shareholders

  • Press releaseBusiness Wire

    IGMS Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of IGM Biosciences, Inc. is Fair to Shareholders

  • Press releasePRNewswire

    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of IGM Biosciences, Inc. - IGMS

  • Avi Kapoor

    Crude Oil Surges 3%; Delta Air Lines Posts Better-Than-Expected Earnings

  • Avi Kapoor

    Nasdaq Down Over 2%; Walgreens Posts Upbeat Results

  • Avi Kapoor

    Dow Dips 500 Points; US Economy Adds 256,000 Jobs In December

  • Rishabh Mishra

    US Stocks To Open On A Tentative Note As Traders Remain Cautious Ahead Of Friday's Crucial Jobs Data

Similar companies

Companies in the same industry as IGM Biosciences LLC

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.